Home > Urology > EAU 2021 > Bladder Cancer > Best of EAU: Highlights on bladder cancer

Best of EAU: Highlights on bladder cancer

Presented By
Prof. Morgan Rouprêt, Pitié-Salpêtrière Hospital, Paris, France
EAU 2021
In the Best of EAU21 session on bladder cancer, Prof. Morgan Rouprêt (Pitié-Salpêtrière Hospital, Paris, France) highlighted 4 noteworthy abstracts [1]. Omitting antimicrobial prophylaxis appears safe in patients undergoing transurethral resection of bladder tumour (TURB); a biomarker test may help to reduce unnecessary cystoscopies in patients with non-muscle invasive bladder cancer (NMIBC); molecular subtyping can improve clinical risk stratification by identification patients at risk of Bacillus Calmette-Guérin (BCG) failure; and nadofaragene firadenovec represents a potential novel treatment option for patients with high-grade BCG-unresponsive NMIBC. Antimicrobial prophylaxis in TURB A multicentre, randomised controlled trial assessed whether omitting antimicrobial prophylaxis is safe in patients undergoing TURB. The primary endpoint was post-operative fever. Of 459 included patients, 202 (44.1%) received antimicrobial pr...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on